Rood's Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients

NCT ID: NCT05882396

Last Updated: 2023-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-01

Study Completion Date

2024-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oxaliplatin-induced chronic peripheral neuropathy is of major concern to oncologists and patients as it has been shown to affect patients' health-related quality of life. Although a number of interventions have been implicated, none of them can be recommended for clinical use. This therapeutic failure reflects a poor understanding of the real mechanism of oxaliplatin-induced neuropathy. However, oxidative stress is identified to be one of the main biomolecular dysfunctions in this neuropathy. Rood's approach is a neurophysiological approach that is based on reflexes of the central nervous system in which the sensory stimulation provides desired muscular response and was specially designed for patients with motor control problems. It was developed by Margeret Rood in 1940. According to Rood, sensory stimulation can activate or deactivate the receptor by facilitation or inhibition, which makes it possible to get the desired muscular response.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

So, the purpose of the study is to investigate the efficiency of Rood's approach on oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Peripheral Neuropathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rood's approach Oxaliplatin-induced peripheral neuropathy Colorectal cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Sixty Patients with colorectal cancer have oxaliplatin-induced peripheral neuropathy. will be indiscriminately assigned to two groups.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rood's approach group

Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.

Group Type ACTIVE_COMPARATOR

Rood's approach

Intervention Type OTHER

Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.

Traditional physical therapy program

Intervention Type OTHER

Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.

Traditional physical therapy program group

Thirty colorectal cancer patients have oxaliplatin-induced peripheral neuropathy.

Group Type ACTIVE_COMPARATOR

Traditional physical therapy program

Intervention Type OTHER

Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rood's approach

Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.

Intervention Type OTHER

Traditional physical therapy program

Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient can participate in the study if they had at least one cycle of oxaliplatin chemotherapy.
* Colorectal cancer patients who have oxaliplatin-induced peripheral neuropathy, the patients included in the study with mild to moderate neuropathy according to mTNS.
* Patients from both genders.
* Their ages range from 18 to 60 years old.

Exclusion Criteria

* Patients who had a history of any other neuropathy as diabetic neuropathy.
* Patients with an unstable medical condition during chemotherapy.
* Patients who are starting new therapy or dose modification during the study period.
* Patients with morbid obesity "body mass index \>40%".
* Patients with a history of non-surgically repaired nerve compression injuries such as carpal tunnel, brachial plexopathy, spinal stenosis, and spinal nerve root compression.
* Patients with a history of central nervous system primary or metastatic malignancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shaimaa Mohamed Ahmed Elsayeh

Lecturer of physical therapy

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shaimaa MA El Sayeh, PhD

Role: PRINCIPAL_INVESTIGATOR

Lecturer at Faculty of Physical Therapy, Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shaimaa MA El Sayeh, PhD

Role: CONTACT

Phone: +201007766160

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P.T.REC/012/004322

Identifier Type: -

Identifier Source: org_study_id